Bortezomib and High-dose Melphalan at Myeloma Relapse
Status:
Unknown status
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The prognosis after retreating with high-dose melphalan with stem cell support after first
relapse after high-dose treatment is dependent on the time to first relapse. Bortezomib can
increase chemosensitivity of e.g. melphalan. The trial aims at determining the toxicity of
adding bortezomib to high-dose melphalan with stem cell support and evaluating whether the
time to a second relapse can be prolonged.